Business Context and Reporting Period
This Form 6-K filing by NewGenIvf Group Limited covers the month of May 2026, specifically reporting on agreements executed on May 28, 2026. The Company, a foreign private issuer, entered into a Share Purchase Agreement and an Exclusive Agency Agreement with PredicXion Group Limited (K25.ai), an APAC-focused AI-powered live-streaming and watch-to-predict platform.
Key Financial Metrics and Transaction Details
The filing details a strategic investment and partnership rather than standard periodic financial results. Key transaction metrics include:
- Initial Equity Acquisition: 2% equity interest in K25.ai for total consideration of US$2,000,000.
- Payment Structure: US$1,000,000 in cash or digital assets (including a US$200,000 prior deposit) and 666,667 newly issued Class A ordinary shares of NewGenIvf.
- Option to Expand: An option to acquire an additional 8% equity interest (totaling up to 10%) at US$1,000,000 per 1% (50% cash, 50% shares), exercisable within three months.
- Revenue Potential: Tiered commission structure on K25.ai's annual gross profit from introduced customers, capped at US$5,000,000 per calendar year.
The filing text does not provide clear values for the Company's current revenue, profit, cash flow, margins, debt, or liquidity positions.
Material Changes and Agreements
The primary material change is the establishment of a strategic partnership with K25.ai. Under the Exclusive Agency Agreement, NewGenIvf is appointed as the exclusive agent for K25.ai in Thailand, Singapore, Japan, and other mutually agreed APAC markets (excluding Mainland China, Hong Kong, and Macau). The agreement has an initial three-year term with automatic one-year renewals, contingent on NewGenIvf meeting a minimum annual gross profit threshold of US$500,000 per territory to maintain exclusivity.
Outlook, Risks, and Contingencies
Management's outlook is tied to the successful closing of the Share Purchase Agreement, which is subject to customary closing conditions. Key risks and contingencies include:
- Performance Thresholds: Failure to meet the US$500,000 annual gross profit threshold in any territory allows K25.ai to terminate NewGenIvf's exclusivity in that region.
- Regulatory Compliance: Shares issued as consideration are "restricted securities" issued under Section 4(a)(2) of the Securities Act and Regulation S, not involving a public offering.
- Market Exposure: The partnership focuses on specific APAC markets, excluding restricted jurisdictions like Mainland China.
Investor Verification Checklist
- Verify the closing conditions for the Share Purchase Agreement and the expected timeline for completion.
- Confirm the valuation of the 666,667 Class A ordinary shares issued as part of the consideration.
- Assess the financial health and operational status of K25.ai to evaluate the viability of the 10% equity option.
- Review the specific performance metrics required to maintain exclusivity in Thailand, Singapore, and Japan.
- Examine the full text of Exhibits 10.1 and 10.2 for detailed legal obligations and termination clauses.